ZENBEXUS (Iberdomide Hydrochloride) Patent Expiration, LOE Window & CMS Spending

ZENBEXUS (Iberdomide Hydrochloride) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2034-10-07 (last listed 2039-09-30), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $29,500 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN221075 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-10-07
Last Listed Patent or Exclusivity Date2039-09-30
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($29,500 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.